OXBRYTA: FDA notice of voluntary market withdrawal
FDA advised clinicians to stop prescribing OXBRYTA after its voluntary withdrawal for safety concerns. This dated market-withdrawal notice is not merely an indication-specific dose restriction.
Selected dated regulatory event; not an exhaustive market-status database. FDA event: 2024-09-26.
Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
The historical OXBRYTA renal subsection remains a source record, but FDA subsequently instructed clinicians to stop prescribing after safety-related withdrawal. This is not a competing renal dose schedule.
Before applying: Do not use historical renal text to justify new prescribing. Follow the FDA safety communication and clinician-guided transition for existing patients; the tool does not recommend an alternative sickle-cell regimen.
Also check: Withdrawal overrides historical renal prescribing context
Rxlist source
GlobalRPh RX List - Voxelotor (Oxbryta Discontinued)
Product / population
Historical OXBRYTA source only; FDA withdrawal notice is separately stored and takes priority over historical prescribing context.
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Regulatory withdrawal is not a renal dose-adjustment disagreement.
Renal dosing, restrictions and evidence limits
The historical renal pharmacokinetic subsection found no clinically meaningful renal effect requiring a derived dose adjustment, and it did not evaluate ESRD requiring dialysis. These old observations are retained only for historical reference. OXBRYTA was withdrawn for safety reasons; the separate FDA notice tells clinicians to stop prescribing it. Do not use the old renal text as a current treatment recommendation.
Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.
Find text within this drug
Find a term without leaving this drug
Search the stored clinical text
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
The historical OXBRYTA renal subsection remains a source record, but FDA subsequently instructed clinicians to stop prescribing after safety-related withdrawal. This is not a competing renal dose schedule.
How to use this: Do not use historical renal text to justify new prescribing. Follow the FDA safety communication and clinician-guided transition for existing patients; the tool does not recommend an alternative sickle-cell regimen.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Rxlist source
GlobalRPh RX List - Voxelotor (Oxbryta Discontinued)
Historical OXBRYTA source only; FDA withdrawal notice is separately stored and takes priority over historical prescribing context.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Important source distinctions
WITHDRAWN PRODUCT: FDA instructed healthcare professionals to stop prescribing OXBRYTA in its September 26, 2024 safety communication. Historical renal text is not current prescribing guidance.
GlobalRPh-hosted RX List · Historical OXBRYTA source only; FDA withdrawal notice is separately stored and takes priority over historical prescribing context.
Renal method: Indexed eGFR below 30 mL/min/1.73 m2; ESRD requiring dialysis not studied. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Historical product / current restriction. Historical renal instructions do not establish current prescribing eligibility. Read the regulatory caution.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
The historical renal pharmacokinetic subsection found no clinically meaningful renal effect requiring a derived dose adjustment, and it did not evaluate ESRD requiring dialysis. These old observations are retained only for historical reference. OXBRYTA was withdrawn for safety reasons; the separate FDA notice tells clinicians to stop prescribing it. Do not use the old renal text as a current treatment recommendation.
RDM40-rxlist-voxelotor-oxbryta-historical-361c9e3e84-C1 · Source locator: Selected renal dosing, renal impairment, toxicity and pharmacokinetic subsections as identified in the summary.
Source-specific limits
Regulatory withdrawal is not a renal dose-adjustment disagreement.
U.S. Food and Drug Administration · FDA September 26, 2024 safety communication; historical renal findings do not restore eligibility.
Renal method: Regulatory safety decision, not a renal dosing threshold. Source date: September 26, 2024 Retrieved: 2026-09-07
Regulatory safety communication. This is a safety restriction, not a dose-adjustment strategy or evidence that a reduced dose is safe.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
FDA tells healthcare professionals to stop prescribing OXBRYTA following voluntary market withdrawal. The communication reports more vaso-occlusive crises and deaths in postmarketing studies and states that the manufacturer ceased distribution, trials and expanded access. Existing patients require clinician-guided transition to another treatment. A historical renal pharmacokinetic statement must not be presented as a current reason to prescribe this product.
RDM40-professional-voxelotor-oxbryta-historical-143f3a56ec-C1 · Source locator: FDA dated safety communication
Additional summaries stored on this page: 0 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.